New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2014
05:36 EDTTEVATeva names Erez Vigodman as CEO
Teva announced that Erez Vigodman, 54, has been appointed president and CEO, effective February 11. Vigodman will succeed acting president and CEO Eyal Desheh, who will return to his previous position as Group EVP and CFO of the company. Vigodman is currently president and CEO of Makhteshim Agan Industries.
News For TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent TEVA news | >>
March 30, 2015
13:11 EDTTEVATeva made 'bold move' with Auspex deal, says BMO Capital
Subscribe for More Information
12:22 EDTTEVAOn The Fly: Midday Wrap
Subscribe for More Information
11:49 EDTTEVAAuspex downgraded to Market Perform from Outperform at BMO Capital
Subscribe for More Information
10:16 EDTTEVAAuspex Pharmaceuticals downgraded to Neutral from Overweight at Piper Jaffray
Subscribe for More Information
09:27 EDTTEVAOn The Fly: Pre-market Movers
Subscribe for More Information
09:15 EDTTEVATeva does not rule out bigger deal if opportunity arises
Subscribe for More Information
09:02 EDTTEVAMylan slips amid Abbott share sale, Teva deal for Auspex
Subscribe for More Information
08:42 EDTTEVATeva says has capacity for additional acquisitions after Auspex deal
Teva (TEVA) says the Auspex (ASPX) transaction is not subject to shareholder approval. Comments from Teva CFO Eyal Desheh speaking on the Teva/Auspex conference call regarding the companies' transaction announced this morning.
07:03 EDTTEVATeva: Auspex deal represents total consideration of $3.2B in enterprise value
Subscribe for More Information
07:01 EDTTEVATeva to acquire Auspex Pharmaceuticals for $101 per share in cash
Subscribe for More Information
07:00 EDTTEVATeva to acquire Auspex Pharmaceuticals for $101 per share in cash
05:55 EDTTEVATeva may be close to large acquisition, Bloomberg reports
Analysts believe Teva may be close to making a large acquisition that could be announced by September, Bloomberg reports. Teva CEO Erez Vigodman said last month hat the company is shifting to an "inorganic growth" strategy, and CRT Capital analyst Timothy Chaing says that "The closer we get to September, the closer they’re going to get to to the finish line on completing a deal or at least announcing a deal." Reference Link
March 27, 2015
07:45 EDTTEVAFDA to hold a public meeting
Subscribe for More Information
07:25 EDTTEVATeva appears to be weighing transformative deal, says Bernstein
After attending Teva's (TEVA) meeting with investors, Bernstein thinks that the company is considering making a 'transformative' acquisition, although it believes that such a deal may not be imminent. The firm sees Mylan ((MYL) and the generic units of Actavis (ACT), Pfizer (PFE), and possibly Valeant (VRX) as the four logical candidates. It says that Teva can pay $81 per share for Mylan, and that a takeover of Mylan would raise Teva's EPS to about $6.50 in 2017 and $7 in 2018. Bernstein raised its price target on Teva to $69 from $60 and keeps an Outperform rating on the shares.
March 26, 2015
07:30 EDTTEVADeutsche Bank to hold a conference
Pharma One-on-One Day is being held in Denver, Colorado on March 26.
March 24, 2015
07:45 EDTTEVAFDA Pediatric Advisory Committee holds a meeting
The Committee discusses pediatric-focused safety reviews, as mandated by the FDA Safety and Innovation Act (FDASIA) for Eli Lilly's Cymbalta, Pfizer's Quillivant XR and Revatio, Johnson & Johnson's Risperdal, GlaxoSmithKline's Advair, HFA Altabax Ointment and Fluarix Quadrivalent, Supernus Pharmaceuticals' Oxtellar XR, Teva Pharmaceutical's Qnasl and Roche's Invirase. The Committee will also discuss the safety ongoing propriety of the humanitarian device exemption for the Medtronic Activa Dystonia Therapy and for the Liposorber LA-15 System in a meeting being held in Silver Spring, Maryland on March 24 at 8 am. Webcast Link
06:22 EDTTEVATeva appointment shows transformative M&A not off table, says Citigroup
Subscribe for More Information
March 23, 2015
16:01 EDTTEVAOptions Update; March 23, 2015
iPath S&P 500 VIX Short-Term Futures down 48c to 25.24 Option volume leaders: AAPL TSLA TWTR GILD CELG FB TSLA AMZN TEVA PBR according to Track Data.
12:10 EDTTEVATeva migraine drug data positive for Amgen, says Piper Jaffray
Piper Jaffray said the "positive" trial data Teva (TEVA) reported for its anti-CGRP antibody in migraines is another important validation for the class of drugs that is also being worked on by Amgen (AMGN), Eli Lilly (LLY) and Alder Biopharmaceuticals (ALDR). The firm said it thinks Amgen is one of the leaders in CGRP antibody space and reiterated its Overweight rating and $187 price target on Amgen shares.
08:50 EDTTEVATeva reports TEV-48125 met endpoints in phase 2b study
Subscribe for More Information
1 | 2 | all recent TEVA news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use